Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TI- A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence (Group) 1 | EXPERIMENTAL | Subjects randomized to Sequence 1 will receive TI in the following sequence: TI-Inhalation Powder A TI-Inhalation Powder B \*30 units (10 units + 20 units) |
| Sequence (Group) 2 | EXPERIMENTAL | Subjects randomized to Sequence 2 will receive TI in the following sequence: TI-Inhalation Powder B TI-Inhalation Powder A \*30 units (10 units + 20 units) |
| Name | Type | Description |
|---|---|---|
| TI-Inhalation Powder A | DRUG | Inhaled Insulin |
| TI-Inhalation Powder B | DRUG | Inhaled Insulin |
Inclusion Criteria: * Men and women aged 18 to 55 years, considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis * HNVs with a screening blood pressure less than 140/90 mm Hg * Subjects who have hypertension controlled with up to 1 medica...
TI-A is an investigational inhaled insulin product developed by MannKind Corporation. It is also known as TI-Inhalation Powder A and is based on the company's Technosphere insulin delivery technology. It is a small molecule therapeutic candidate that has been studied in a Phase 1 clinical trial involving healthy adult volunteers.
TI-A is being developed as an inhaled insulin therapy. The specific disease indication for TI-A has not been publicly disclosed by the developer. Its only recorded clinical study enrolled healthy volunteers rather than patients with a defined condition, so the target indication remains undisclosed at this stage of development.
TI-A is developed by MannKind Corporation, which trades on the Nasdaq under the ticker MNKD. MannKind is the sponsor of the clinical program for TI-A and its associated inhalation powder formulation. The drug is based on the company's Technosphere insulin delivery platform.
TI-A is in Phase 1 clinical development. It is an investigational product and is not approved by the FDA. MannKind Corporation has completed one Phase 1 trial of TI-A, and no active trials of the drug are currently listed. Further development status has not been announced.
TI-A has been studied in one completed Phase 1 trial, NCT01982604, titled Comparison of 30 Units of TI (Technosphere Insulin) Prepared With Insulin From Two Different Suppliers. The trial enrolled 38 healthy adult volunteers in the United States, was randomized and controlled, and did not use blinding. No active trials are listed.
Yes. TI-A and TI-Inhalation Powder A refer to the same MannKind Corporation investigational product. TI-A is the short name, while TI-Inhalation Powder A describes the inhaled powder formulation. Both names point to the same Phase 1 small molecule program studied under NCT01982604.